BioCardia Inc:製品パイプライン分析

◆英語タイトル:BioCardia Inc - Product Pipeline Analysis, 2017 Update
◆商品コード:DATA8010088
◆発行会社(調査会社):GlobalData
◆発行日:2017年12月27日
◆ページ数:31
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:医療機器
◆販売価格オプション(消費税別)
Single UserUSD750 ⇒換算¥109,500見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD1,500 ⇒換算¥219,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD2,250 ⇒換算¥328,500見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
BioCardia Inc (BioCardia) is a clinical-stage regenerative medicine company that develops novel therapeutics for cardiovascular diseases. The company develops biotherapeutic candidate, which include CardiAMP cell therapy system, an autologous minimally processed bone marrow cells; and CardiALLO cell therapy system, an allogeneic off the shelf mesenchymal stem cell product candidate for ischemic systolic heart failure. Its CardiAMP cell therapy system comprises cell potency screening test, a point of care cell processing platform, and a biotherapeutic delivery system. BioCardia also offers catheters for use in delivery of therapeutic agents directly to the heart, and of guiding catheters for use in peripheral and coronary vasculature and chambers of the heart. The company sells its products through a network of distributors across the US. BioCardia is headquartered in San Carlos, California, the US.

This report is a source for data, analysis, and actionable intelligence on the company’s portfolio of pipeline products. The report provides key information about the company, its major products and brands.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage.

Scope:

- The report reviews detailed company profile with information on business description, key company facts, major products and services, key competitors, key employees, locations and subsidiaries and recent developments
- The report analyzes all pipeline products in development for the company BioCardia Inc
- The report provides pipeline analysis on all pipeline products of the company (by equipment type, by indication, by development stage, and by trial status)
- The report covers detailed information on each pipeline product with information on pipeline territory, stage of development, device class, regulatory path, indication(s), application(s) and estimated launch date
- The report provides detailed description of products in development, technical specification and functions
- The report also covers ongoing clinical trials (wherever applicable) with information on trial name, trial objective, sponsor, trial design , trial status and phase, estimated start and end date.

Reasons to Buy:

- Develop business strategies by understanding the trends and developments driving the medical devices pipeline and technology landscape
- Design and develop your product development, marketing and sales strategies by understanding the competitor portfolio
- To formulate effective Research & Development strategies
- Develop market-entry and market expansion strategies
- Exploit in-licensing and out-licensing opportunities by identifying products, most likely to ensure a robust return
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop competition strategies by identifying the status and likely launch of the competitors’ pipeline products through review of the clinical trials, stage and of development, etc
- Identify, understand and capitalize the next high-value products that your competitor would add in its portfolio

Note: Some sections may be missing if data is unavailable for the company

【レポートの目次】

Table of Contents
Table of Contents 2
List of Tables 3
List of Figures 3
BioCardia Inc Company Overview 4
BioCardia Inc Company Snapshot 4
BioCardia Inc Pipeline Products and Ongoing Clinical Trials Overview 4
BioCardia Inc – Pipeline Analysis Overview 7
BioCardia Inc – Key Facts 7
BioCardia Inc – Major Products and Services 8
BioCardia Inc Pipeline Products by Development Stage 9
BioCardia Inc Ongoing Clinical Trials by Trial Status 11
BioCardia Inc Pipeline Products Overview 13
CardiAMP – Heart Failure 13
CardiAMP – Heart Failure Product Overview 13
CardiAMP – Heart Failure Clinical Trial 14
CardiAMP – Post Acute Infarction 15
CardiAMP – Post Acute Infarction Product Overview 15
Helix Transendocardial Delivery System 16
Helix Transendocardial Delivery System Product Overview 16
Helix Transendocardial Delivery System Clinical Trial 17
BioCardia Inc – Key Competitors 19
BioCardia Inc – Key Employees 20
BioCardia Inc – Locations And Subsidiaries 21
Head Office 21
Recent Developments 22
BioCardia Inc, Recent Developments 22
Nov 10, 2017: BioCardia Reports Third Quarter 2017 Financial Results and Business Highlights 22
Nov 07, 2017: Dr. Ian McNiece Appointed BioCardia Chief Scientific Officer 22
Oct 04, 2017: BioCardia Receives U.S. Patent Covering Morph Product Family Design 23
Sep 27, 2017: BioCardia Announces Successful Interim Safety Analysis in Its Phase 3 Clinical Trial of CardiAMP Stem Cell Therapy for Heart Failure 23
Sep 19, 2017: BioCardia Announces Publication of 12-Month Results from Phase II TRIDENT Clinical Trial that Shows Positive Safety Profile for Allogeneic Bone Marrow Stem Cells Delivered with Helix Transendocardial Delivery System 24
Sep 15, 2017: BioCardia’s CardiAMP Heart Failure Trial Design to be Presented at Texas Heart Institute International Symposium on Cardiovascular Regenerative Medicine 24
Jul 26, 2017: BioCardia Completes Roll-in Cohort in Pivotal Phase III CardiAMP Heart Failure Trial 25
May 24, 2017: Study Shows Helix Transendocardial Delivery System Enables Greater Myocardial Retention of Stem Cell Therapy 26
Feb 28, 2017: Johns Hopkins Medicine, Maryland Stem Cell Research Fund and BioCardia Announce First Patient Treated with CardiAMP Cell Therapy for Ischemic Heart Failure in Phase III Clinical Trial 26
Dec 29, 2016: CardiAMP Pivotal Heart Failure Trial Initiated at Two US Centers 27
Appendix 28
Methodology 28
About GlobalData 30
Contact Us 30
Disclaimer 31

List of Tables
BioCardia Inc Pipeline Products and Ongoing Clinical Trials Overview 4
BioCardia Inc Pipeline Products by Equipment Type 5
BioCardia Inc Pipeline Products by Indication 6
BioCardia Inc Ongoing Clinical Trials by Trial Status 6
BioCardia Inc, Key Facts 7
BioCardia Inc, Major Products and Services 8
BioCardia Inc Number of Pipeline Products by Development Stage 9
BioCardia Inc Pipeline Products Summary by Development Stage 10
BioCardia Inc Ongoing Clinical Trials by Trial Status 11
BioCardia Inc Ongoing Clinical Trials Summary 12
CardiAMP - Heart Failure - Product Status 13
CardiAMP - Heart Failure - Product Description 13
CardiAMP - Heart Failure - Randomized Controlled Pivotal Trial of Autologous Bone Marrow Mononuclear Cells Using the CardiAMP Cell Therapy in Patients with Post Myocardial Infarction Heart Failure: CardiAMP Heart Failure Trial 14
CardiAMP - Post Acute Infarction - Product Status 15
CardiAMP - Post Acute Infarction - Product Description 15
Helix Transendocardial Delivery System - Product Status 16
Helix Transendocardial Delivery System - Product Description 16
Helix Transendocardial Delivery System - A Multicentric Controlled Phase I / IIb Study Evaluating the Safety and the Efficacy of in Vitro Expanded Peripheral Blood CD34+ Stem Cells Output by the StemXpand Automated Process, and Injected in Patients with an Acute Myocardial Infarction and a Left Ventricle Ejection Fraction (LVEF) Remaining Below or Equal to 45% after PTCA and Stent(s) Implantation Versus Standard of Care 17
Helix Transendocardial Delivery System - A Phase II, Randomized, Blinded, Study of the Safety and Efficacy of Transendocardial Injection of Allogeneic Human Mesenchymal Stem Cells (hMSCs) (20 Million or 100 Million Total MSCs) in Patients with Chronic Ischemic Left Ventricular Dysfunction Secondary to Myocardial Infarction 17
Helix Transendocardial Delivery System - Phase I Trial of Endocavitary Injection of Bone Marrow Derived CD133+ Cells in Ischemic Refractory Cardiomyopathy (RECARDIO Trial) 18
BioCardia Inc, Key Employees 20
Glossary 29

★海外企業調査レポート[BioCardia Inc:製品パイプライン分析]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Covestro AG (1COV):企業の財務・戦略的SWOT分析
    Covestro AG (1COV) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and th …
  • Pharma Foods International Co Ltd (2929):企業の財務・戦略的SWOT分析
    Summary Pharma Foods International Co Ltd (Pharma Foods) operates as a manufacturer and marketer of functional food ingredients and health food products. The company provides products such as ovopron, gamma aminobutyric acid, tasty catechin, alpha lipoic acid, bonepep, runpep and folic acid enriched …
  • Calixar SAS:製薬・医療:M&Aディール及び事業提携情報
    Summary Calixar SAS (Calixar) is a provider of solutions to develop conformational antibodies. The company offers production, Solubilization, extraction, purification, stabilization and crystallization of functional membrane proteins and antigens. It offers technology to discover and validate the po …
  • F-star Biotechnology Ltd-製薬・医療分野:企業M&A・提携分析
    Summary F-star Biotechnology Ltd (F-star) is a drug development company that offers novel bispecific antibodies. The company develops immuno-oncology bispecific antibody therapeutics. Its technologies comprise modular antibody technology, a proprietary engine that generates bispecific antibodies; mA …
  • KVK-Tech Inc-製薬・医療分野:企業M&A・提携分析
    Summary KVK-Tech Inc (KVK-Tech) is a manufacturer and marketer generic drugs. The company's product portfolio includes benzphetamine HCL, betaxolol, chlorphen-12, cyclobenzaprine HCL, diethylpropion HCL, hydroxyzine HCL, indomethacin extended release, phendimetrazine tartrate, phentermine HCL, prome …
  • Grupo Biotoscana SL (GBIO33):製薬・医療:M&Aディール及び事業提携情報
    Summary Grupo Biotoscana SL (Biotoscana) is a biopharmaceutical company that develops, manufactures and markets advanced medicines for unmet medical needs. The company offers products such as vidaza, ladevina, zyvalix, mielozitidina, votrynib, bozob, timab, enzastar, capebina, leprid, olvestran, toc …
  • Sabre Corporation (SABR):企業の財務・戦略的SWOT分析
    Sabre Corporation (SABR) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses …
  • Gale Pacific Ltd (GAP):企業の財務・戦略的SWOT分析
    Gale Pacific Ltd (GAP) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses an …
  • OraSure Technologies Inc (OSUR)-医療機器分野:企業M&A・提携分析
    Summary OraSure Technologies Inc (OraSure) is a manufacturer and distributor of oral fluid specimen collection devices, diagnostic products and other medical devices. Its product portfolio encompasses infectious disease tests for the detection of antibodies for the HIV and Hepatitis C virus; and ant …
  • Lonestar Heart Inc:製薬・医療:M&Aディール及び事業提携情報
    Summary Lonestar Heart Inc (Lonestar Heart) is a pharmaceutical company that focuses on the development of novel cardiac restorative therapies for advanced heart failure. The company offers Algisyl cardiac implantable hydrogel and MyoTec system. Its Algisyl product provides a new treatment option fo …
  • Medicago Inc:製薬・医療:M&Aディール及び事業提携情報
    Summary Medicago Inc (Medicago), a subsidiary of Mitsubishi Tanabe Pharma Corp is a clinical-stage biotechnology company that develops and produces vaccines and antibodies. The company concentrates on the discovery and development of novel vaccines and therapeutic proteins for infectious diseases. I …
  • Saint-Gobain Weber GmbH:企業の戦略・SWOT・財務情報
    Saint-Gobain Weber GmbH - Strategy, SWOT and Corporate Finance Report Summary Saint-Gobain Weber GmbH - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service off …
  • Recondo Technology Inc:医療機器:M&Aディール及び事業提携情報
    Summary Recondo Technology Inc (Recondo) is a provider of cloud-based software and services that streamline operations in the healthcare industry. The company provides Empowered Patient Access, Empowered Business Office, and Empowered Technology solutions to connect providers with payers and their p …
  • Santee Cooper:電力:M&Aディール及び事業提携情報
    Summary Santee Cooper (Santee), formerly South Carolina Public Service Authority, is a state-owned electric and water utility. The company generates the electricity from coal, natural gas, nuclear, hydro, biomass, landfill, and solar sources. It purchases, sells, and exchanges energy with other bulk …
  • Asos Plc:企業の戦略・SWOT・財務分析
    Asos Plc - Strategy, SWOT and Corporate Finance Report Summary Asos Plc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions, …
  • ENN Energy Holdings Ltd (2688):企業の財務・戦略的SWOT分析
    ENN Energy Holdings Ltd (2688) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakn …
  • Banco de Sabadell, S.A.:戦略・SWOT・企業財務分析
    Banco de Sabadell, S.A. - Strategy, SWOT and Corporate Finance Report Summary Banco de Sabadell, S.A. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service off …
  • Atrion Corp (ATRI):企業の財務・戦略的SWOT分析
    Atrion Corp (ATRI) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and th …
  • Puretech Health plc (PRTC):企業の財務・戦略的SWOT分析
    Summary Puretech Health plc (Puretech), formerly PureTech Ventures LLC, is a biopharmaceutical company that develops medicines for diseases caused by dysfunctions in the nervous, gastrointestinal, and immune systems. The company develops a microbiome immune system drug-discovery platform and drug ca …
  • Broadcom Inc (AVGO):企業の財務・戦略的SWOT分析
    Broadcom Inc (AVGO) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and t …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆